Abstract:ObjectivesThe proarrhythmic risk of QT prolonging drugs varies significantly. However, the mechanisms responsible for the high or low risk of drug-induced arrhythmias remain unknown. In this study, we tested our hypothesis that a proarrhythmic window exists for drugs that block multiple ion channels, which may be a cause of drugs with a high or low risk of proarrhythmia. Based on date from single cell research, tolterodine (a bladder inotropic drug), amiodarone and ranolazine are used as multiple channel inhibitors.MethodsHearts from New Zealand White female rabbits weighing 2.5-3.5 kg were isolated, perfused in a Langendorff mode with modified Krebs-Hensileit solution. The atrioventricular nodal area was thermally ablated to produce complete atrioventricular block, and then heart was paced at a frequency of 1 Hz. Multiple channel monophasic action potentials (MAP) and pseudo 12-lead electrocardiograms (ECGs) were recorded. MAPD90 and transmural dispersion of repolarization (TDR) were measured.ResultsIn the absence of a drug (control), MAPD90s recorded from epicardium and endocardium of left ventricule were 186.5 ± 5.5 and 206.5 ± 5.1 ms (n = 8), respectively. Administration of tolterodine from 10 nM to 600 nM, MAPD90 was increased, in concentration dependent manners, from 196.7.0 ± 4.9 to 281.7 ± 26.8 ms, and 220.0 ± 4.6 ms to 350.6 ± 18.7 ms (n = 8, p < 0.001 vs control), respectively. However, when the concentration of tolterodine increased to 10 µM from 600 nM, MAPD90 was decreased to 224.2 ± 5.9 and 252.5 ± 5.9 ms (n = 8), respectively. In addition, the incidence of TdP was correlated with the biphasic changes of MAPD90. Polymorphic ventricular tachycardias (PVT) were recorded at concentrations of 0.1-1 µM. There was no arrhythmia in the presence of 100-600 nM and 3-10 µM tolterodine. In contrast, amiodarone caused PVT only at 0.03-0.3 µM in the presence of late INa enhancer ATX-II. Ranolazine prolonged MAPD90 in absence, but not in the presence of ATX-II and caused no PVT.ConclusionsThe biphasic pattern of MAPD induced by tolterodine, as well as by amiodarone and ranolazine, suggests that a proarrythmic window exists in multiple ion channel blockers, which may be a determinator of the risk of drug-induced proarrhythmias. The mechanism of the biphasic change may be attributed to the relative selectivity of drug on IK and late INa.

Analysis of risk factors for QT interval prolongation induced by intravenous amiodarone administration

The effects of amiodarone on QT dispersion in patients with atrial fibrillation

Risk factors of liver injury induced by intravenous administration of amiodarone: a multicenter analysis

The effect of amiodarone on heart rate variability in patients with idiopathic dilated cardiomyopathy

QT Prolongation Preceding Ventricular Fibrillation After Amiodarone Administration: A Case Report

Case Report: Amiodarone-induced multi-organ toxicity

QT interval prolongation in patients with acute ischemic stroke: a report in northwest China

Amiodarone-induced hepatic injury

Data-driven drug-induced QT prolongation surveillance using adverse reaction signals derived from 12-lead and continuous electrocardiogram data

A Rare Case of Intravenous Amiodarone Toxicity

The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review

Diagnosis and Treatment of Drug Induced Acquired Long QT Syndrome

Effects of Amiodarone and Esmolol for Heart Rate and Cardiovascular Changes

The chinical value of intravenous amiodarone for fast atrial fibrillation in patients with acute myocardial infarction

A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS

GW24-e2999 Proarrhythmic window of a drug determines the risk of multiple ion channel inhibitors

Amiodarone-Induced Liver Attenuation on CT Scan: Alarming Signal for Toxicity and Prompt Discontinuation

Effect of amiodarone hydrochloride tablets combined with potassium magnesium aspartate on hemodynamics and cardiac function in patients with coronary heart disease and arrhythmia

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

The Effect of QT Dispersion on Cases of Acute Myocardial Infarction Treated by Percutaneous Transluminal Coronary Angioplasy

Amiodarone-induced Thyroid Dysfunction in Taiwan: a Retrospective Cohort Study